101.93
price down icon1.05%   -1.08
pre-market  Vorhandelsmarkt:  102.10   0.17   +0.17%
loading
Schlusskurs vom Vortag:
$103.01
Offen:
$103
24-Stunden-Volumen:
907.25K
Relative Volume:
1.07
Marktkapitalisierung:
$24.50B
Einnahmen:
$3.13B
Nettoeinkommen (Verlust:
$-381.72M
KGV:
-63.54
EPS:
-1.6042
Netto-Cashflow:
$-2.15B
1W Leistung:
-7.98%
1M Leistung:
-9.63%
6M Leistung:
-6.31%
1J Leistung:
+15.57%
1-Tages-Spanne:
Value
$101.67
$103.02
1-Wochen-Bereich:
Value
$101.52
$112.90
52-Wochen-Spanne:
Value
$81.20
$131.49

Biontech Se Adr Stock (BNTX) Company Profile

Name
Firmenname
Biontech Se Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
6,772
Name
Twitter
@BioNTech_Group
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
BNTX's Discussions on Twitter

Vergleichen Sie BNTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BNTX
Biontech Se Adr
101.93 24.76B 3.13B -381.72M -2.15B -1.6042
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.05 99.76B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
579.61 62.21B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
452.33 59.53B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
704.07 43.33B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.96 35.68B 3.81B -644.79M -669.77M -6.24

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-05 Bestätigt H.C. Wainwright Buy
2025-05-29 Eingeleitet Goldman Neutral
2025-03-13 Eingeleitet Citigroup Buy
2025-01-10 Eingeleitet Truist Buy
2024-12-11 Eingeleitet Wells Fargo Overweight
2024-12-02 Bestätigt BMO Capital Markets Outperform
2024-11-19 Eingeleitet Berenberg Buy
2024-11-19 Hochstufung Evercore ISI In-line → Outperform
2024-11-08 Hochstufung Goldman Neutral → Buy
2024-09-24 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-09-17 Hochstufung Jefferies Hold → Buy
2024-09-16 Hochstufung JP Morgan Underweight → Neutral
2024-08-07 Hochstufung Deutsche Bank Hold → Buy
2024-08-02 Hochstufung HSBC Securities Hold → Buy
2024-05-14 Eingeleitet Evercore ISI In-line
2024-02-23 Eingeleitet BMO Capital Markets Outperform
2024-01-05 Eingeleitet Oppenheimer Perform
2023-12-01 Herabstufung JP Morgan Neutral → Underweight
2023-10-16 Herabstufung HSBC Securities Buy → Hold
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-17 Hochstufung Redburn Neutral → Buy
2022-12-15 Hochstufung BofA Securities Neutral → Buy
2022-08-17 Eingeleitet Cowen Market Perform
2022-07-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-07-06 Fortgesetzt Canaccord Genuity Buy
2022-02-01 Hochstufung Redburn Sell → Neutral
2021-12-16 Eingeleitet Morgan Stanley Equal-Weight
2021-11-10 Hochstufung H.C. Wainwright Neutral → Buy
2021-10-22 Eingeleitet Deutsche Bank Hold
2021-10-07 Eingeleitet Jefferies Hold
2021-08-11 Hochstufung Bryan Garnier Neutral → Buy
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-06-16 Herabstufung Redburn Neutral → Sell
2021-05-18 Eingeleitet Goldman Neutral
2021-05-11 Herabstufung Bryan Garnier Buy → Neutral
2020-12-01 Herabstufung BofA Securities Buy → Neutral
2020-08-03 Fortgesetzt Berenberg Buy
2020-07-21 Hochstufung BofA Securities Neutral → Buy
2020-06-30 Herabstufung H.C. Wainwright Buy → Neutral
2020-05-19 Hochstufung H.C. Wainwright Neutral → Buy
2020-04-28 Herabstufung BofA/Merrill Buy → Neutral
2020-03-18 Herabstufung JP Morgan Overweight → Neutral
2020-03-09 Eingeleitet H.C. Wainwright Neutral
2020-01-24 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-01-22 Herabstufung UBS Buy → Neutral
2019-11-05 Eingeleitet Wolfe Research Outperform
2019-11-04 Eingeleitet Berenberg Buy
2019-11-04 Eingeleitet BofA/Merrill Buy
2019-11-04 Eingeleitet Canaccord Genuity Buy
2019-11-04 Eingeleitet JP Morgan Overweight
2019-11-04 Eingeleitet SVB Leerink Outperform
2019-11-04 Eingeleitet UBS Buy
Alle ansehen

Biontech Se Adr Aktie (BNTX) Neueste Nachrichten

pulisher
01:54 AM

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

01:54 AM
pulisher
Aug 27, 2025

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 - GlobeNewswire Inc.

Aug 27, 2025
pulisher
Aug 26, 2025

BioNTech SE Sponsored ADR $BNTX Shares Acquired by HighTower Advisors LLC - Defense World

Aug 26, 2025
pulisher
Aug 25, 2025

Cresset Asset Management LLC Sells 1,035 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World

Aug 25, 2025
pulisher
Aug 22, 2025

BioNTech SE Sponsored ADR $BNTX Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Aug 22, 2025
pulisher
Aug 20, 2025

BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN

Aug 20, 2025
pulisher
Aug 20, 2025

BioNTech’s Promising NSCLC Study: A Potential Game-Changer in Cancer Treatment - MSN

Aug 20, 2025
pulisher
Aug 19, 2025

BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - TipRanks

Aug 19, 2025
pulisher
Aug 18, 2025

Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer - TipRanks

Aug 18, 2025
pulisher
Aug 18, 2025

BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily

Aug 18, 2025
pulisher
Aug 18, 2025

HC Wainwright Has Bearish Estimate for BioNTech Q3 Earnings - Defense World

Aug 18, 2025
pulisher
Aug 16, 2025

BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

US Bancorp DE Cuts Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

BioNTech (NASDAQ:BNTX) Price Target Lowered to $136.00 at HC Wainwright - Defense World

Aug 15, 2025
pulisher
Aug 14, 2025

BioNTech’s BNT113 Trial: A Potential Game-Changer in Head and Neck Cancer Treatment - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - TipRanks

Aug 13, 2025
pulisher
Aug 12, 2025

BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

BioNTech’s New Study on Breast Cancer Treatment: A Potential Game-Changer? - TipRanks

Aug 12, 2025
pulisher
Aug 09, 2025

BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

BioNTech SE’s BNT331 Safety Trial: A Potential Game-Changer in Women’s Health - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

BioNTech’s BNT327 Study: A New Hope for Advanced Lung Cancer Treatment - TipRanks

Aug 07, 2025
pulisher
Aug 06, 2025

BioNTech ADR Earns RS Rating Upgrade - Investor's Business Daily

Aug 06, 2025
pulisher
Aug 06, 2025

BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail

Aug 06, 2025
pulisher
Aug 05, 2025

BioNTech SE Earnings Call: Strategic Growth Amid Challenges - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

BioNTech Earnings: Guidance Reiterated; Incremental Progress in Clinical Trials - Morningstar

Aug 05, 2025
pulisher
Aug 05, 2025

Kylian Mbappe fires out strong message after taking iconic No. 10 shirt at Real Madrid - Goal.com

Aug 05, 2025
pulisher
Aug 04, 2025

BioNTech ADR Earns Relative Strength Rating Upgrade - MSN

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Aug 04, 2025
pulisher
Aug 02, 2025

BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - The Globe and Mail

Aug 02, 2025
pulisher
Aug 02, 2025

BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World

Aug 02, 2025
pulisher
Jul 30, 2025

BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.

Jul 30, 2025
pulisher
Jul 29, 2025

Best Momentum Stocks to Buy for July 29th - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

New Strong Buy Stocks for July 29th - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World

Jul 29, 2025
pulisher
Jul 27, 2025

Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 27, 2025
pulisher
Jul 25, 2025

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva

Jul 25, 2025
pulisher
Jul 24, 2025

BioNTech’s Promising Study on Pancreatic Cancer Treatment: Market Implications - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks

Jul 22, 2025

Finanzdaten der Biontech Se Adr-Aktie (BNTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$134.97
price up icon 0.33%
$24.42
price down icon 1.55%
biotechnology ONC
$297.96
price down icon 0.73%
$83.70
price down icon 1.34%
$25.11
price up icon 1.33%
Kapitalisierung:     |  Volumen (24h):